2Maes B, Hadaya K, de Moor B, et al. Severe diarrhea in renal transplant patients : results of the DIDACT study [ J ]. Am J Trans- plant, 2006, 6(6) : 1466 - 1472.
3Rubin RH. Gastrointestinal infectious disease complications fol- lowing transplantation and their differentiation from immunosup- pressant-reduced gastrointestinal toxicities [ J ]. Clin Transplant, 2001, 15(Suppl 4) : 11 -22.
4Sellin JH. The pathophysiology of diarrhea [ J ]. Clin Transplant, 2001, 15(Suppl 4) : 2 -10.
5Lee RA, Gabardi S. Current trends in immunosuppressive thera- pies for renal transplant recipients[ J]. Am J Health Syst Pharm, 2012, 69 (22): 1961-1975.
6Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant re- cipients : meta-analysis and meta-regression of randomised trial da- ta[J]. BMJ, 2005, 331(7520): 810-886.
7Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus based regimens versus taerolimus and mycophenolate mofetil in renal allograft trcipients [ J ]. Am J Transplant, 2011, 11 : 1633 - 1644.
8HellerT, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolie acid aeylglueuronide are no tassoeiated with diarrhea in renal transplant recipients [J]. Am J Transplant, 2007, 7 (7) : 1822 -1831.
9Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of myco- phenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients[J].Clin Transplant, 2005, 19 (6) : 779 -784.
10Hardinger KL, Hebbar S, Bloomer T, et al. Adverse drug reaction driven immunosuppressive drug manipulations: A single-center comparison of enteric-coated mycophenolate sodium vs. mycophe- nolate mofetil[ J]. Clin Transolant, 2008, 22(5): 555- 561.
